Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Cancer Research Australia.
Статті в журналах з теми "Cancer Research Australia"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Cancer Research Australia".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Lacey, Karen, Penelope Schofield, Meinir Krishnasamy, Carrie Lethborg, Elizabeth Cashill, Eileen Thompson, Jill Butty, et al. "Universal truths: Learning from the experience of cancer patients in Australia and England." Journal of Clinical Oncology 32, no. 30_suppl (October 20, 2014): 255. http://dx.doi.org/10.1200/jco.2014.32.30_suppl.255.
Повний текст джерелаАнотація:
255 Background: Self-reported patient experience data is vital to the design of responsive and relevant health services. Annual Cancer Patient Experience Surveys in England (NHS-CPES) have been used to effectively guide and monitor improvements in patient experience. This study measured baseline cancer patient experience in member hospitals of the Victorian Comprehensive Cancer Centre in Australia, and benchmarked this with cancer patients in England. Methods: The NHS-CPES instrument and methodology was used. A paper-based questionnaire was mailed to 5,722 admitted patients aged >18 years with an eligible ICD-10 code. Australian results were compared to 71,793 patients in England from the 2011/12 NHS-CPES. Results: 37% (2,101) patients responded. Most patients rated their overall care as very good or excellent (91% Australia, 88% England). Having a named nurse specialist was a key predictor of experience. Patients with a specialist nurse were significantly more positive in 50 questions in Australia (77%) and 64 questions in England (98%) compared to patients without one. In both countries, patients with rarer cancers tended to be less positive than those with other cancer types. Australian patients with brain/central nervous system cancers and sarcomas gave the lowest score in 46 questions (71%). Patients with a disability or a long-term condition, and those from minority ethnic groups were also less positive. Relevant patient information was lacking; only 65% of patients in Australia and 77% in England were given understandable written information specific to their care, and a little over half received information about financial entitlements (58% Australia, 52% England). Conclusions: Cancer patient experience using the NHS-CPES has been successfully measured and compared across two different health systems. Findings in Australia are similar to those in England suggesting the same key issues affect all cancer patients. Important areas for quality improvement include the provision of tailored written patient information and the provision of named nurse specialists as part of the model of care. Acknowledgement: The authors thank Quality Health Limited for data analysis and the NHS for permitting use of the NHS-CPES.
2
Grogan, P. "Bowel Cancer Screening in Australia: Research and Tactics to Achieve an Advocacy Goal." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 145s. http://dx.doi.org/10.1200/jgo.18.14500.
Повний текст джерелаАнотація:
Background and context: Bowel cancer is the second leading cause of cancer death in Australia, yet survival is above 90% if it is detected at stage one. Cancer Council Australia has advocated since 1997 (when RCT evidence was published) for a national government-run screening program—a challenge to any government, given the costs and changes across the health system, irrespective of the health benefits. Cancer Council Australia has advocated at every step in the program’s development, from pilot studies to securing bipartisan political support for the program´s introduction to funding allocations linked to our budget submissions. Yet cost pressures restricted the Australian Government in 2013 to implementation by 2034 - an unacceptable timeframe in view of preventable deaths over that period. To find a peer-reviewed “big number” to convince candidates in Australia´s 2013 federal election to support full implementation by 2020, Cancer Council commissioned a study of multiple screening scenarios submitted to a leading medical journal, showing our implementation plan would prevent 35,000 bowel cancer deaths by 2040. The incoming government, despite campaigning on national debt-reduction, allocated almost $100 million dollars—the centrepiece of its first health budget—to Cancer Council Australia´s plan, attributing the decision to our advice. Subsequent Cancer Council Australia research has shown the program´s life-saving benefits to be even greater if participation can be increased, and that it would achieve net savings. We continue to push for program promotion, with our peer-reviewed research showing 60% participation would prevent 84,000 bowel cancer deaths by 2040. Aim: To highlight how political advocacy and scientific research can work together by ensuring the advocacy is based on the best available evidence, with that evidence collected through a peer-reviewed study designed to deliver major policy reform. Strategy/Tactics: The key strategy/tactics were basic but often overlooked: collect the most compelling evidence of benefit, thereby making it difficult for politicians to dismiss the advocacy. The example of bowel cancer screening advocacy in Australia since 2012-13 has been presented in Australian research institutes to highlight how studies can be designed expressly to translate to a major policy outcome. Program/Policy process: Cancer Council Australia adhered to all government processes within its advocacy remit (budget submissions, being appointed to government committees, producing clinical practice guidelines) while working independently to drive the research and public policy agenda. Outcomes: The accelerated implementation of a landmark national screening program. What was learned: That even politicians obsessed with budget cuts can´t always argue with the best evidence—and that researchers can design studies that change policy and practice, if guided by political pragmatists.
3
Long, R., K. Cooper, A. Woods, C. Biondi, J. Luzuriaga, P. Jackson, C. Anderiesz, C. Giles, and H. Zorbas. "‘Bridging the Continuum' - Reporting Population-Level Trends Across the Continuum of Care: The Australian National Cancer Control Indicator (NCCI) Web Site." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 78s. http://dx.doi.org/10.1200/jgo.18.61200.
Повний текст джерелаАнотація:
Background: High-quality data can assist the development of policy and cancer strategies, stimulate lines of research, and inform the provision of care leading to better cancer outcomes. In November 2017 Cancer Australia launched the National Cancer Control Indicators (NCCI) Web site ( https://ncci.canceraustralia.gov.au ), Australia's first interactive Web site of cancer-specific, national population-based data across the continuum of care. The NCCI Web site presents a set of indicators for monitoring national cancer trends and benchmarking internationally across seven key aspects of cancer control; prevention, screening, diagnosis, treatment, psychosocial care, research and outcomes. Aim: By presenting a set of indicators using seven domains from the cancer care continuum, the NCCI Web site presents the most current Australian national data for a range of cancer control indicators in an accessible and interactive format. The primary aim of the NCCI Web site (hosted as part of the Cancer Australia Web site) is to monitor and report the most recent population-level trends to drive improvements across the cancer control continuum in Australia, and to facilitate international benchmarking of Australia's cancer control efforts. Methods: National data level on 33 individual measures across the seven cancer continuum domains was accessed from both government and nongovernment data custodians. Where applicable and available for measures, data were disaggregated and presented by age, sex, indigenous status, remoteness area of residence and socioeconomic status. Review of the data analysis was undertaken by 46 external reviewers including data custodians and subject matter experts. Results: Example summary data from several indicators across the NCCI Web site, including demographic disaggregation by age, sex, remoteness area of residence and socioeconomic status (where available) will be provided. e.g., • Smoking prevalence has decreased substantially over the past 30 years, and smoking rates among both adolescents and adults in Australia are among the lowest in the world. • Cancer mortality rates have been falling steadily since 1995, across most cancer types. Australia has lower mortality rates from cancer when compared with most other similar developed countries, about 6% lower than the estimated global average in 2012. National population-level data showing incidence by stage at diagnosis for the top five most common cancers has also been reported on the Web site - making Australia one of the few countries in the world where these data are available. Conclusion: The NCCI Web site is a flagship data Web site providing, for the first time, an evolving high-level national data resource to monitor Australian population-level trends in cancer control across the continuum. As one of the very few cross-continuum cancer reporting resources in the world, this is a valuable resource for use by those within the international cancer control community.
4
Biondi, Christine, Vivienne Milch, Van Nguyen, Regina Ryan, David Roder, Alan Woods, Kristie Cooper, Rhona Wang, Cleola Anderiesz, and Dorothy Mary Kate Keefe. "The COVID-19 pandemic led to a reduction in cancer services in Australia." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e18812-e18812. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18812.
Повний текст джерелаАнотація:
e18812 Background: Australian oncologists reported dramatic decreases in cancer referrals during the pandemic. As real time data were difficult to acquire, Cancer Australia used surrogate measures to infer where reductions in medical services occurred. We analysed data available through the Medicare Benefits Schedule (MBS), a list of the medical services and professional attendances subsidised by the Australian Government, for the five highest incidence cancers: breast, colorectal, lung, prostate, and skin cancers. Methods: We identified over 500 MBS item codes for diagnostic and treatment procedures for malignancies and pre-cancerous conditions. Item codes were categorised into analysis groups based on cancer type and/or similarities in type of service. Data were examined at national and jurisdictional levels for 2020 to determine reductions during the initial COVID-19 period and to monitor subsequent recovery. Data were compared to 2019 to account for normal seasonal variation. Results: Australia’s first wave of the pandemic ran from March to May, and a second wave in the state of Victoria alone ran from July to September 2020. We observed notable reductions across all diagnostic and surgical procedure groups examined, with initial reductions observed between March and April for diagnostic procedures, and a one-month delay for surgical procedures, between April and May. Some services showed an initial recovery in May, with many showing partial or full recovery by June. For some groups, analyses showed sustained reductions over the 12-month period. While COVID-19 case numbers were greater during the second wave, the impact on services was less pronounced, likely owing to more refined policy approaches to managing health system and workforce capacity. There was further recovery by September for some but not all services. Similar patterns of change were observed across all Australian states and territories, with some variation by jurisdiction. Conclusions: The pandemic has impacted the delivery of cancer care. Any potential delays in diagnoses and treatment due to these reductions in services may lead to more advanced cancer stage at diagnosis and poorer patient outcomes including recurrence and survival. Impact of COVID-19 on selected cancer services in Australia in 2020.[Table: see text]
5
Dussel, Veronica, Kira Bona, John A. Heath, Joanne M. Hilden, Jane C. Weeks, and Joanne Wolfe. "Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer." Journal of Clinical Oncology 29, no. 8 (March 10, 2011): 1007–13. http://dx.doi.org/10.1200/jco.2009.27.8960.
Повний текст джерелаАнотація:
Purpose Financial concerns represent a major stressor for families of children with cancer but remain poorly understood among those with terminally ill children. We describe the financial hardship, work disruptions, income loss, and coping strategies of families who lost children to cancer. Methods Retrospective cross-sectional survey of 141 American and 89 Australian bereaved parents whose children died between 1990 and 1999 and 1996 to 2004, respectively, at three tertiary-care pediatric hospitals (two American, one Australian). Response rate: 63%. Results Thirty-four (24%) of 141 families from US centers and 34 (39%) of 88 families from the Australian center reported a great deal of financial hardship resulting from their children's illness. Work disruptions were substantial (84% in the United States, 88% in Australia). Australian families were more likely to report quitting a job (49% in Australia v 35% in the United States; P = .037). Sixty percent of families lost more than 10% of their annual income as a result of work disruptions. Australians were more likely to lose more than 40% of their income (34% in Australia v 19% in the United States; P = .035). Poor families experienced the greatest income loss. After accounting for income loss, 16% of American and 22% of Australian families dropped below the poverty line. Financial hardship was associated with poverty and income loss in all centers. Fundraising was the most common financial coping strategy (52% in the United States v 33% in Australia), followed by reduced spending. Conclusion In these US and Australian centers, significant household-level financial effects of a child's death as a result of cancer were observed, especially for poor families. Interventions aimed at reducing the effects of income loss may ease financial distress.
6
Long, R., A. Woods, C. Biondi, J. Luzuriaga, C. Anderiesz, P. Jackson, C. Giles, and H. Zorbas. "Collection and Reporting of National Cancer Stage at Diagnosis Data in Australia (STaR Project)." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 67s. http://dx.doi.org/10.1200/jgo.18.61300.
Повний текст джерелаАнотація:
Background: Stage at diagnosis is an important prognostic factor for cancer, providing contextual information for interpreting population health indicators such as mortality from cancer and cancer survival. Australian population-based cancer registries (PBCRs) routinely collect information on cancer incidence and mortality. The need for high quality, comprehensive national data on stage at diagnosis to supplement these data are widely recognized in Australia. The collection and dissemination of quality national stage data will enhance the: • ability to better monitor cancer outcomes, inform cancer control policy; • understand variations across different populations; and • identify where further research and targeted strategies may be required to improve cancer outcomes. Linking data on cancer stage at diagnosis with other administrative cancer data will also allow for a better understanding of the relationship between stage at diagnosis, treatments received, patterns of cancer recurrence, and survival outcomes. Aim: To strengthen national data capacity by collecting and reporting cancer stage at diagnosis for Cancer Australia's Stage, Treatment and Recurrence (STaR) project. Methods: Working with state and territory population-based cancer registries (PBCRs) and the Australian Pediatric Cancer Registry, Cancer Australia supported the development and testing of Business Rules for the collection of national cancer stage at diagnosis for: • The top 5 incident cancers based on the Tumor, Node, and Metastasis (TNM) staging system. These rules were endorsed by the Australasian Association of Cancer Registries (AACR) as a national standard in May 2016; and • Childhood cancers, with a separate set of Business Rules for 16 childhood cancer types based on the Toronto Pediatric Cancer Stage Guidelines. These rules were supported by the AACR as a national standard. Results: Using the AACR-endorsed Business Rules, comprehensive national cancer stage at diagnosis data for the top 5 incident cancers (for 2011) have been collected in Australia for the first time. Over 90% of incidence cases were able to be assigned a value for registry-derived (RD) stage at diagnosis for melanoma (97%), prostate (97%), and female breast (94%) cancers. Lower staging completeness was found for colorectal cancers (88%), and for lung cancers (72%). Business Rules for the collection of stage at diagnosis data for pediatric cancers have also been developed; 93% of sample cases diagnosed in the period 2006-2010 were able to be staged, ranging from 84% for nonrhabdomyosarcoma to 100% for hepatoblastoma. Conclusion: The Business Rules enabled the uniform collection of cancer stage at diagnosis data for the first time in Australia. The collection of these data will allow for the linkage of stage at diagnosis to other sources of information, including patterns of treatments applied, and enable reporting of survival and recurrence outcomes by stage.
7
Thoumi, Andrew, Gerald B. Fogarty, Elizabeth J. Paton, and Stephen Shumack. "Is the contribution of Australian research to the national 2019 clinical practice guidelines for keratinocyte cancer adequate? A simple analysis." International Journal of Radiology & Radiation Therapy 8, no. 4 (October 12, 2021): 144–54. http://dx.doi.org/10.15406/ijrrt.2021.08.00307.
Повний текст джерелаАнотація:
Introduction: The Australian 2002 National Health and Medical Research Council (NHMRC) treatment guidelines for non-melanoma skin cancer (NMSC) were updated in 2008. At this time, the lack of high-quality Australian research conducted between 2002 to 2008 was noted. The primary aim of the present study was to assess the improvement in the quantity and quality of Australian research in the 2019 keratinocyte cancer guidelines. Secondary aims included an assessment of the quantity and quality of Australian research in comparison to the guidelines provided by the other selected countries, and an evaluation of the improvements in the Australian contribution since 2008. Method: Surgical (Sx) and radiotherapy (RT) treatment sections were interrogated. The analysis was simple. Each reference was counted as one unit. The quantity assessment was carried out by categorizing the references according to their country of origin: Australia, United Kingdom (UK), United States (US) and European Union (EU) countries, which were grouped as one country (EU) for the purpose of this study. The number of references from each country were then added up. To assess for quality, all references were ranked according to the American Society of Plastic Surgeons (ASPS) rating scale. A quality ratio for each country was then calculated by dividing the total number of prospective trials (i.e., levels I and II) by the number of retrospective studies (level III and lower) from each country if the numbers were sufficient. To evaluate the Australian improvement since 2008, Australian references were first categorized according to their year of publication (2002 to 2017), and then allocated to one of four bins of class intervals representing time periods. Results: Twenty-five of the 133 Sx references in the 2019 guidelines were Australian, which was less than the US (58) and EU (37), but better than the UK (12). Quality ratios were: Australia 0.8, UK 1.4, US 0.31, and EU 0.48. Of the 238 RT references, Australia contributed 53, US 107, EU 62, and UK 16. Quality ratios were: Australia 0.06, UK 0.3, US 0.18, and EU 0.34. Australia’s contribution to the UK and US RT guidelines were evaluated. For the UK RT guidelines (11 references), Australia contributed 3, UK 1, US 2 and EU 5. For the US ASTRO guidelines (101 references), Australia contributed 20, UK 1, US 44 and EU 36. Quality ratios were Australia 0.11, US 0.19 and EU 0.2. For Australian research overtime (2002-2017), the quantity and quality of Sx papers are decreasing; whereas for RT, the quantity is increasing but the quality remains poor. Conclusion: The contribution of Australian research to Australia’s own keratinocyte cancer guidelines is not the highest and did not improve over the period of evaluation. The same can be stated for Australia’s research contribution to the UK and US RT guidelines. Australia needs to do more high-quality research.
8
Swenson, Wade T., Emily Westergard, and Abigail Paige Swenson. "Rural health cancer care: A literature review." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e18500-e18500. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18500.
Повний текст джерелаАнотація:
e18500 Background: A recent review of the medical literature of rural health cancer care delivery has not been published. We conducted a preliminary review of the last twenty years of rural health cancer care delivery literature utilizing medical subject headings (MeSH) within the PubMed NCBI) database. Methods: Using PubMed MeSH Major Topic terms “rural population” and “cancer” we identified publications published from 2000 to 2020. We searched PubMed for publications that included the major topic MeSH terms “rural population” and “cancer”. We individually reviewed articles, confirmed the focus of the article, and subcategorized the articles. Results: We identified 580 publications which met the search criteria, the majority were focused on the United States (266), followed by China (56), Australia (54), and India (27). Among the publications focusing on the United States, 76 involved Appalachian States. Kentucky (18) and Georgia (10) were the states most frequently represented. Malignancies most commonly represented were: breast cancer (148), uterine/cervical (84), and colorectal cancers (68). The journals which published the most rural health cancer care delivery were The Journal of Rural Health (42), Asian Pacific Journal of Cancer Prevention (20), Cancer (14), Rural and Remote Health (13), Journal of Cancer Education (13), Australian Journal of Rural Health (12). Conclusions: The rural health cancer care literature in the last two decades focuses primarily on the United States, China, Australia, and India. Within the United States, the research focus is Appalachia. The majority of articles focus on breast cancer, uterine/cervical, and colorectal cancers. The journal which published the majority of rural health cancer care articles was the Journal of Rural Health.
9
Ong, Hock Soo, and B. Mark Smithers. "Gastric cancer in Australia." Gastric Cancer 5, no. 2 (June 2002): 118–21. http://dx.doi.org/10.1007/s101200200020.
Повний текст джерела
10
Youlden, Danny R., Peter D. Baade, Patricia C. Valery, Leisa J. Ward, Adele C. Green, and Joanne F. Aitken. "Childhood cancer mortality in Australia." Cancer Epidemiology 36, no. 5 (October 2012): 476–80. http://dx.doi.org/10.1016/j.canep.2012.06.001.
Повний текст джерела
11
Georgiou, Chloe L., Damien Kee, Lia Papadopoulos, Reece Caldwell, Allison Bourne, Javier Haurat, Maureen Turner, David Goldstein, and Clare L. Scott. "Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e18581-e18581. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18581.
Повний текст джерелаАнотація:
e18581 Background: Rare cancers (RC) occur at incidence < 6/100,000 and accessing treatment and evidence-based care can be challenging. Australia’s geographical distance adds complexity when referring to RC sub-specialists, clinical trials or research. The Australian Rare Cancer (ARC) Portal aims to address this unmet need. Methods: The ARC Portal is a free online academic referral hub designed to facilitate rare cancer clinical care and research. Registered cancer specialists can request RC guidelines, expert advice and molecular testing/interpretation. Patient consent allows researchers access to de-identified clinical data, with optional consent for biospecimen access, for dedicated rare cancer research projects (Melbourne Health HREC/15/MH/396). Portal case reports are collated by research fellows with reference to published evidence and expert opinion to inform treating clinician decision making. Surveys are sent at 3 time points following case completion to assess the ARC Portal impact on patient management. The ARC Portal is funded by Omico, with support from BioGrid Australia, Rare Cancers Australia and the Stafford Fox Rare Cancer Program. Results: Over two years, 924 patients have been enrolled into the ARC Portal. Demographics include 73% females, 27% males, at different disease stages from initial diagnosis (23%), on relapse/ progression (48%) or with stable disease/in remission (29%). The spread of incidence of individual cancers varied from 6/100,000 to < 0.1/100,000. Primary tumour types include gynaecological (44.4%), gastrointestinal (19%), thoracic (6%), ocular (5.2%), soft tissue (3.8%), breast (3.6%), skin (3.0%), and CNS tumors (2.5%). Endocrine, head and neck, urological, and cancers of unknown primary comprised the remaining 12.5% of cases. Longer term follow up of 100 cases demonstrated ARC Portal reports impacted clinician decision making in at least 42%. This included subsequent lines of treatment, molecular testing access or clinical trial enrolment. Conclusions: The ARC Portal uses an online centralized streamlined approach to overcome challenges and inequities inherent in rare cancer care, by optimizing clinician access to RC expertise and clinical trials; and to facilitate future RC discoveries by enabling research through collection of clinical data and accessible annotated biospecimens.
12
Gambini, Emanuela. "In the Aftermath of D’Arcy v. Myriad Genetics Inc: Patenting Isolated Nucleic Acids in Australia." European Journal of Risk Regulation 7, no. 2 (June 2016): 451–59. http://dx.doi.org/10.1017/s1867299x00005882.
Повний текст джерелаАнотація:
On 7 October 2015 the High Court of Australia unanimously allowed the appeal on D’Arcy v. Myriad Genetics Inc and ordered that claims 1, 2 and 3 of Australian Patent No 686004, entitled “In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene”, be revoked.The High Court's judgment overturned the decisions of Justice Nicholas of the Federal Court, at first instance, and the Full Federal Court. This case note provides an overview of the High Court's decision and discusses its meaning and implications for patenting isolated nucleic acids in Australia.
13
Ritchie, D. S. "DC research in Australia." Cytotherapy 9, no. 3 (2007): 225–30. http://dx.doi.org/10.1080/14653240701306212.
Повний текст джерела
14
Baade, Peter D., Lin Fritschi, and Elizabeth G. Eakin. "Non-Cancer Mortality among People Diagnosed with Cancer (Australia)." Cancer Causes & Control 17, no. 3 (April 2006): 287–97. http://dx.doi.org/10.1007/s10552-005-0530-0.
Повний текст джерела
15
Der Vartanian, Carolyn, Vivienne Milch, Gail Garvey, Cleola Anderiesz, Jane Salisbury, Candice-Brooke Woods, Melissa Austen, Rhona Wang, and Dorothy Mary Kate Keefe. "COVID-19 and cancer: Strategic health promotion for indigenous Australians during a pandemic." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e24028-e24028. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e24028.
Повний текст джерелаАнотація:
e24028 Background: Given the impact of COVID-19 on Indigenous and ethnic minority populations observed globally, keeping COVID-19 out of vulnerable Aboriginal and Torres Strait Islander (Indigenous Australian) communities remains a priority. Compared to non-Indigenous Australians, Indigenous Australians experience disparities in cancer incidence and outcomes due to social disadvantage, increased cancer-related modifiable risk factors, poorer access to health services and lower participation in screening. During the pandemic, cancer-related investigations and treatment reduced significantly in Australia, leading to potential decreases in cancer diagnoses and consequences for future survival outcomes. Concerned about the risk of morbidity and mortality due to COVID-19 for Indigenous Australians, as well as worsening cancer outcomes, Cancer Australia undertook strategic health promotion initiatives, to inform and support optimal cancer care. Methods: In consultation with respected Indigenous colleagues to ensure cultural appropriateness of language and information, we published a dedicated webpage titled ‘ Cancer and COVID-19 – what it means for our Mob*’ with tailored information, advice, and links to key resources and support services for Indigenous Australians. We also released a video titled ‘ Act early for our Mob’s Health’, providing targeted, culturally appropriate, consumer-friendly information to encourage Indigenous Australians to see their doctor or Aboriginal Health Worker with symptoms that may be due to cancer. Results: The information hub has been well-received among the Indigenous Australian community, receiving over 3,200 visits, and the social media campaigns have received over 1.4 million impressions and 46,000 video views between mid-March 2020 to mid-February 2021. This campaign has supported proactivity among the Indigenous population in keeping their communities safe during the pandemic, maintaining a population rate of COVID-19 of less than one percent of all confirmed cases in Australia. Conclusions: Culturally appropriate information and resources developed through the process of co-design can help to influence positive health behaviour change in Indigenous populations. We predict that our strategic, multi-channel health promotion campaign is contributing to keeping the Indigenous Australian community safe and informed during the pandemic, with additional work needed to monitor cancer rates and outcomes and address the ongoing information needs of the community. *Mob is a colloquial term to identify a group of Indigenous Australians associated with a family or community from a certain place.
16
Fraser, Jennifer. "Rendering Inuit cancer “visible”: Geography, pathology, and nosology in Arctic cancer research." Science in Context 33, no. 3 (September 2020): 195–225. http://dx.doi.org/10.1017/s0269889721000016.
Повний текст джерелаАнотація:
ArgumentIn August of 1977, Australian pathologist David W. Buntine delivered a presentation at the Annual Meeting of the Royal College of Pathologists of Australia in Melbourne, Victoria. In this presentation, he used the diagnostic category of “Eskimoma,” to describe a unique set of salivary gland tumors he had observed over the past five years within Winnipeg’s Health Sciences Center. Only found amongst Inuit patients, these tumors were said to have unique histological, clinical, and epidemiological features and were unlike any other disease category that had ever been encountered before. To understand where this nosological category came from, and its long-term impact, this paper traces the historical trajectory of the “Eskimoma.” In addition to discussing the methods and infrastructures that were essential to making the idea of Inuit cancer “visible,” to the pathologist, the epidemiologist, and to society at large, this paper discusses how Inuit tissue samples obtained, stored, and analyzed in Winnipeg, Manitoba, came to be codified into a new, racially based disease category – one that has guided Canadian and international understandings of circumpolar cancer trends and shaped northern healthcare service delivery for the past sixty years.
17
Giles, Graham, Keith Waters, Vicky Thursfield, and Helen Farrugia. "Childhood cancer in Victoria, Australia, 1970–1989." International Journal of Cancer 63, no. 6 (December 11, 1995): 794–97. http://dx.doi.org/10.1002/ijc.2910630608.
Повний текст джерела
18
Tyczyński, J., W. Tarkowski, D. M. Parkin, and W. Zatoński. "Cancer mortality among Polish migrants to Australia." European Journal of Cancer 30, no. 4 (January 1994): 478–84. http://dx.doi.org/10.1016/0959-8049(94)90423-5.
Повний текст джерела
19
McWhirter, William R., Cecily Dobson, and Ian Ring. "Childhood cancer incidence in Australia, 1982–1991." International Journal of Cancer 65, no. 1 (January 3, 1996): 34–38. http://dx.doi.org/10.1002/(sici)1097-0215(19960103)65:1<34::aid-ijc7>3.0.co;2-2.
Повний текст джерела
20
Schell, Dominique, Shahid Ullah, Mark E. Brooke-Smith, Paul Hollington, Marina Yeow, Christos S. Karapetis, David I. Watson, Stephen J. Pandol, Claire T. Roberts, and Savio G. Barreto. "Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017." Cancers 14, no. 2 (January 6, 2022): 275. http://dx.doi.org/10.3390/cancers14020275.
Повний текст джерелаАнотація:
Background & Aims: Globally, there has been a concerning rise in the incidence of young-onset cancers. The aim of this study was to provide trends in the incidence and survival of gastrointestinal adenocarcinomas (oesophagus, stomach, pancreas, and colorectal) in South Australia over a 27-year period. Methods: This is a cross-sectional analysis of a prospective longitudinal database including all cases of gastrointestinal adenocarcinomas prospectively reported to the South Australian (State) Cancer Registry from 1990 to 2017. Results: A total of 28,566 patients diagnosed with oesophageal, stomach, pancreatic, or colorectal adenocarcinoma between 1990 and 2017 were included in the study. While the overall incidence for gastrointestinal adenocarcinomas in individuals >50 years has decreased since 2000 (IRR of 0.97 (95% CI 0.94–1.00; p = 0.06)) compared to 1990–1999, the rate amongst individuals aged 18–50 has significantly increased (IRR 1.41 (95% CI 1.27–1.57; p < 0.001)) during the same reference time period. Although noted in both sexes, the rate of increase in incidence was significantly greater in males (11.5 to 19.7/100,000; p < 0.001). The overall survival from adenocarcinomas across all subsites improved in the >50-year cohort in the last decade (HR 0.89 (95% CI 0.86–0.93; p < 0.001)) compared to 1990–1999. In individuals aged 18–50 years, there has only been a significant improvement in survival for colorectal cancer (HR 0.82 (95% CI 0.68–0.99; p < 0.04)), but not the other subsites. A lower overall survival was noted for males in both age cohorts (18–50 years—HR 1.24 (95% CI 1.09–1.13; p < 0.01) and >50 years—HR 1.13 (95% CI 1.10–1.16; p < 0.001), respectively) compared to females. Conclusions: This study from South Australia demonstrates a significant increase in young-onset gastrointestinal adenocarcinomas over the last 28 years, with a greater increase in the male sex. The only significant improvement in survival in this cohort has been noted in colorectal cancer patients.
21
Flander, Louisa, Evelien Dekker, Berit Andersen, Mette Bach Larsen, Robert J. Steele, Nea Malila, Tytti Sarkeala, et al. "What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia?" Cancer Control 29 (January 2022): 107327482211213. http://dx.doi.org/10.1177/10732748221121383.
Повний текст джерелаАнотація:
Background Colorectal cancer (CRC) is the second most diagnosed cancer in men and women and second most common cause of cancer death in Australia; Australia’s CRC incidence and mortality are among the world’s highest. The Australian National Bowel Cancer Screening Program began in 2006; however, only 33% of those approached for the first time by the Program between 2018 and 2019 returned the kit. Of the 5.7 million kits sent during this period, only 44% were returned. Our aim was to identify practices and features of national bowel cancer screening programs in countries with similar programs but higher screening participation, to identify potential interventions for optimising Australian CRC screening participation. Methods We searched published and grey literature for CRC screening programs reporting at least 50% screening participation using postal invitation and free return of iFOBT home kits. Interviews were conducted with cancer registry staff and academic researchers, focused on participant and practitioner engagement in screening. Results National programs in Netherlands, Scotland, Denmark, and Finland reported over 50% screening participation rates for all invitation rounds. Shared characteristics include small populations within small geographic areas relative to Australia; relatively high literacy; a one-sample iFOBT kit; national registration systems for population cancer screening research; and screening program research including randomised trials of program features. Conclusions Apart from the one-sample kit, we identified no single solution to persistent Australian low uptake of screening. Research including randomised trials within the program promises to increase participation. Impact This screening program comparison suggests that within-program intervention trials will lead to increased Australian screening participation.
22
Butow, Phyllis Noemi, Lynley Aldridge, Melanie Bell, Ming Sze, Maurice Eisenbruch, Madeleine King, Michael Jefford, Penelope Schofield, Priya Duggal-Beri, and David Goldstein. "Cancer survivorship outcomes in immigrants." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6111. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6111.
Повний текст джерелаАнотація:
6111 Background: Immigration is increasing world-wide. Cancer survivorship is now recognised as a period of difficult adjustment for all patients, and possibly more so for immigrants. We explored disparities in quality of life outcomes for immigrant (IM) versus Anglo-Australian (AA) cancer survivors. Methods: In a cross-sectional design, cancer survivors were recruited through the New South Wales, Queensland and Victorian Cancer Registries in Australia. IM participants, their parents and grandparents were born in a country where Chinese, Greek, or Arabic is spoken and spoke one of those languages. AAs were born in Australia and spoke English. All were diagnosed with cancer 1-3 years previously. Questionnaires (completed in preferred language) included the Hospital Anxiety and Depression Scale (anxiety/ depression), FACT-G (quality of life) and Supportive Care Needs Survey (unmet needs). Outcomes were compared between AA and IM groups in adjusted regression models that included age, gender, socio-economic status, education, marital status, religion, time since diagnosis and cancer type (prostate, colorectal, breast and other). Results: There were 599 participants (response rate 41%). Consent was unrelated to demographic and disease variables. AA and IM groups were similar except that immigrants had higher proportions in the low and highly educated groups (p < 0.0001), and higher socioeconomic status (p = 0.0003). In adjusted analyses (see table), IMs had clinically significant higher depression (possible range 0-21), greater unmet information and physical needs, and lower quality of life than AAs. The possible range for the latter three is 0-100. Conclusions: Immigrants experience poorer outcomes in cancer survivorship, even after adjusting for socio-economic, demographic and disease differences. Interventions are required to improve their adjustment after cancer. Results highlight areas of unmet need that might be better addressed by the health system (particularly with regard to provision of information and support. [Table: see text]
23
Chuen Li, Shu, Fei-Li Zhao, Raj Gauba, Keri Yang, Soraya Azmi, and Constantine Si Lun Tam. "Population-wide patterns of care in chronic lymphocytic leukemia in Australia: An analysis of the pharmaceutical benefits scheme dataset." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e19518-e19518. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19518.
Повний текст джерелаАнотація:
e19518 Background: The treatment landscape in patients with chronic lymphocytic leukemia (CLL) is changing with the approvals of Bruton’s tyrosine kinase inhibitors (BTKis) in Australia. We sought to understand the practice impact of the introduction of publicly funded novel agents for the treatment of CLL. The objective of this study was to describe the evolving treatment patterns of Australian patients with CLL over the last 10 years using population-wide prescription records. Methods: Patients who initiated a treatment for CLL between 01/01/2011 and 07/31/2021 were extracted from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset. This dataset includes the dispensing records for 10% of the Australian population and captures all publicly funded treatments in Australia. The index date was defined as the commencement of any drug for the treatment of CLL. First-line (1L) therapy was defined as the first treatments prescribed for CLL. A patient was defined as relapsed/refractory (R/R) if they had commenced a drug which was in a different therapeutic category, or if they re-started the same regimen after a gap of more than 180 days. Descriptive analyses were conducted to examine the use of treatment regimens for the overall 10-year population by line of therapy. Analyses by calendar year were also performed to assess changes in treatment patterns. Results: Overall, 803 patients with CLL were identified. The majority of patients were male (65%) and age > 60 years (77%), with most being aged 70-79 years (33% of total). Many patients were receiving comedications at baseline, including antihypertensives (47%), antipsychotics or antidepressants (17%), and/or anticoagulants (13%). In the overall population (2011-2021), the majority of patients had received 1L treatment with fludarabine-cyclophosphamide-rituximab (FCR, 49%), chlorambucil ± CD20 (27%), or CD20 monotherapy (17%). The most commonly used regimens in R/R patients at any subsequent episode of treatment included CD20 monotherapy (56%), BTKi (41%) or FCR (33%). A trend in adoption of novel agents was observed throughout the years following their PBS listing. Analysis by calendar year showed that from 2011 to 2020 use of FCR in 1L decreased from 78% to 10%; and use of BTKis in R/R increased from 0% to 62%. Conclusions: CLL treatment patterns have significantly changed in Australia since the introduction of the BTKis (e.g., ibrutinib, acalabrutinib). The use of FCR in 1L CLL has decreased and use of BTKis in R/R patients has increased.
24
Chuen Li, Shu, Fei-Li Zhao, Raj Gauba, Keri Yang, Soraya Azmi, and Constantine Si Lun Tam. "Population-wide patterns of care in chronic lymphocytic leukemia in Australia: An analysis of the pharmaceutical benefits scheme dataset." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e19518-e19518. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19518.
Повний текст джерелаАнотація:
e19518 Background: The treatment landscape in patients with chronic lymphocytic leukemia (CLL) is changing with the approvals of Bruton’s tyrosine kinase inhibitors (BTKis) in Australia. We sought to understand the practice impact of the introduction of publicly funded novel agents for the treatment of CLL. The objective of this study was to describe the evolving treatment patterns of Australian patients with CLL over the last 10 years using population-wide prescription records. Methods: Patients who initiated a treatment for CLL between 01/01/2011 and 07/31/2021 were extracted from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset. This dataset includes the dispensing records for 10% of the Australian population and captures all publicly funded treatments in Australia. The index date was defined as the commencement of any drug for the treatment of CLL. First-line (1L) therapy was defined as the first treatments prescribed for CLL. A patient was defined as relapsed/refractory (R/R) if they had commenced a drug which was in a different therapeutic category, or if they re-started the same regimen after a gap of more than 180 days. Descriptive analyses were conducted to examine the use of treatment regimens for the overall 10-year population by line of therapy. Analyses by calendar year were also performed to assess changes in treatment patterns. Results: Overall, 803 patients with CLL were identified. The majority of patients were male (65%) and age > 60 years (77%), with most being aged 70-79 years (33% of total). Many patients were receiving comedications at baseline, including antihypertensives (47%), antipsychotics or antidepressants (17%), and/or anticoagulants (13%). In the overall population (2011-2021), the majority of patients had received 1L treatment with fludarabine-cyclophosphamide-rituximab (FCR, 49%), chlorambucil ± CD20 (27%), or CD20 monotherapy (17%). The most commonly used regimens in R/R patients at any subsequent episode of treatment included CD20 monotherapy (56%), BTKi (41%) or FCR (33%). A trend in adoption of novel agents was observed throughout the years following their PBS listing. Analysis by calendar year showed that from 2011 to 2020 use of FCR in 1L decreased from 78% to 10%; and use of BTKis in R/R increased from 0% to 62%. Conclusions: CLL treatment patterns have significantly changed in Australia since the introduction of the BTKis (e.g., ibrutinib, acalabrutinib). The use of FCR in 1L CLL has decreased and use of BTKis in R/R patients has increased.
25
Woods, R. L. "Australia." Lung Cancer 1, no. 1-2 (August 1985): 23. http://dx.doi.org/10.1016/s0169-5002(85)80138-0.
Повний текст джерела
26
Then, Shih-Ning. "Regulation of Human Stem Cell Research in Australia." Stem Cell Reviews and Reports 5, no. 1 (February 13, 2009): 1–5. http://dx.doi.org/10.1007/s12015-009-9055-3.
Повний текст джерела
27
Budd, Alison C., and Christine J. Sturrock. "Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination." Sexual Health 7, no. 3 (2010): 328. http://dx.doi.org/10.1071/sh09133.
Повний текст джерелаАнотація:
Cytological and cancer surveillance will provide the most effective indications of short-term effects and long-term outcomes of the introduction of the human papillomavirus (HPV) vaccine in Australia. This article outlines how this surveillance is proposed to occur through the established national monitoring mechanisms of the National Cervical Screening Program in the annual Australian Institute of Health and Welfare (AIHW) publication ‘Cervical screening in Australia’. Cytological surveillance will be possible principally through cytology data provided annually by the state and territory cervical cytology registers, and it is expected that these data will provide the earliest and most comprehensive indications of effects from the HPV vaccine. Some potential issues in interpreting these data are also discussed, including the potentially confounding effects of the introduction of new National Health and Medical Research Council guidelines ‘Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities’ some 9 months before the introduction of the vaccine. Cancer surveillance over the long term will be possible using cervical cancer incidence data reported annually for the National Cervical Screening Program in ‘Cervical screening in Australia’ using data sourced from the Australian Cancer Database. In a final discourse, the HPV vaccine and cervical screening are discussed concurrently, and the importance of continued cervical screening in the HPV vaccine era emphasised.
28
Buettner, Petra G., and Beverly A. Raasch. "Incidence rates of skin cancer in Townsville, Australia." International Journal of Cancer 78, no. 5 (November 23, 1998): 587–93. http://dx.doi.org/10.1002/(sici)1097-0215(19981123)78:5<587::aid-ijc10>3.0.co;2-e.
Повний текст джерела
29
Tam, Constantine Si Lun, Fei-Li Zhao, Tom Liu, Raj Gauba, Shu Chuen Li, and Boxiong Tang. "Population-wide patterns of care in mantle cell lymphoma in Australia: An analysis of the pharmaceutical benefits scheme dataset." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e19587-e19587. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19587.
Повний текст джерелаАнотація:
e19587 Background: The treatment landscape in patients with mantle cell lymphoma (MCL) is changing with the introduction of Bruton’s tyrosine kinase inhibitors (BTKis) and bendamustine in Australia. We sought to analyze the practice impact of the introduction of publicly funded novel agents in MCL. The objective of this study was to describe the evolving treatment patterns of Australian patients with MCL over the last 10 years using population-wide prescription records. Methods: Patients who initiated a treatment for MCL between 01/01/2011 and 07/31/2021 were extracted from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset, which includes the dispensing records for 10% of the Australian population. This dataset captures all publicly funded treatments in Australia. The index date was defined as the commencement of any drug for MCL. First-line (1L) therapy was defined as the first treatments prescribed for MCL. A patient was defined as relapsed/refractory (R/R) if they had commenced a drug which was in a different therapeutic category, or if they re-started the same regimen after a gap of more than 180 days. Descriptive analyses were conducted to examine the use of treatment regimens for the overall 10-year population by line of therapy. Analyses by calendar year were also performed to assess the changes in the treatment patterns. Results: Overall, 241 patients with MCL were identified over the study period. The majority of patients were male (68.4%), age > 60 years (84.9%), and most being aged 70-79 years (42.1% of total). Many patients were receiving comedications at baseline, including antihypertensives (44.1%), anticoagulants (14.5%), and/or antipsychotics or antidepressants (12.5%). In the overall population (2011-2021), the majority of patients had received 1L treatment with bendamustine-rituximab (BR, 53.9%), rituximab plus other regimens (27.6%), or rituximab monotherapy (11.2%). The most commonly used regimens in R/R patients at any subsequent episode of treatment included BTKi (66.3%), rituximab monotherapy (52.8%) or rituximab plus other regimens (31.5%). A trend in adoption of novel agents was observed throughout the years following their PBS listing. Analysis by calendar year showed that from 2011 to 2020 for 1L therapy, the use of BR increased from 0% to 50% and use of rituximab-containing regimen except BR decreased from 100% to 16.7%; use of BTKi increased in R/R patients from 0% to 74.7%. Conclusions: MCL treatment patterns have significantly changed in Australia since the introduction of BTKis and bendamustine-containing regimens. The use of rituximab-containing regimens except BR in 1L MCL has decreased and use of BTKis in R/R patients has increased.
30
Goldstein, David, Ming Sze, Melanie Bell, Madeleine King, Michael Jefford, Maurice Eisenbruch, Afaf Girgis, Lisa Vaccaro, and Phyllis Noemi Butow. "Disparities in quality-of-life outcomes in immigrant cancer patients." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e16507-e16507. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16507.
Повний текст джерелаАнотація:
e16507 Background: Immigration is increasing world-wide. We explored disparities in quality of life outcomes for immigrant (IM) versus Anglo-Australian (AA) cancer patients having anti-cancer treatment. Methods: In a cross-sectional design, cancer patients were recruited through outpatient Oncology clinics in New South Wales, Victoria, and the Northern Territory in Australia. IM participants, their parents and grand parents were born in a country where Chinese, Greek, or Arabic is spoken and spoke one of those languages. AAs were born in Australia and spoke English. All were diagnosed with cancer < 1 year previously. Questionnaires (completed in preferred language) included the Hospital Anxiety and Depression Scale (anxiety/depression), FACT-G (quality of life) and the Supportive Care Needs Survey (unmet needs). Adjusted regression models comparing AA and IM groups included age, gender, socio-economic status, education, marital status, religion, time since diagnosis, and cancer type (colorectal, breast, lung, other). Results: There were 910 participants (response rate 57%). IM were similar to AA, except that IM were more likely to be married (76 vs 67 %, p = 0.01) and in the low and the highly educated groups (p < 0.0001). In adjusted analyses, IMs had clinically significant higher anxiety, greater unmet information and physical needs and lower quality of life than AAs (see table). The possible ranges are 0-21 for anxiety and depression, and 0-100 otherwise. Conclusions: In this hospital-based study with a high rate of advanced disease, immigrants with cancer experienced poorer quality of life outcomes, even after adjusting for socio-economic, demographic, and disease variables. Interventions are required to improve their experience of cancer care. Results highlight areas of unmet need that might be better addressed by the health system (particularly with regards to provision of information and meeting support and physical needs). [Table: see text]
31
Potente, Sofia, Vanessa Rock, Jacqueline McIver, Melinda Williams, Christopher Magee, and Kathy Chapman. "Fighting Skin Cancer With a Musical Sound." Social Marketing Quarterly 19, no. 4 (September 30, 2013): 279–89. http://dx.doi.org/10.1177/1524500413506583.
Повний текст джерелаАнотація:
Australian youth have good knowledge about skin cancer prevention as a result of over three decades of traditional mass media campaigns. However, youth sun protection behavior remains poor. This case study describes the results of a unique social marketing campaign (the Sun Sound) aimed at translating youths’ knowledge into improved sun protection behavior. Formative research identified that a key barrier to sun protection was youth regularly forgot to protect their skin. As such, the campaign centered on a musical jingle that was broadcast at outdoor recreational settings as a “cue to action” reminder to use sun protection at the time and point of sun exposure. The Sun Sound was trialed at two coastal communities in New South Wales, Australia, during summer 2009–2010. The media launch generated 17.6 million Australian audience impressions (advertising value A$257,785). Intercept surveys conducted with 467 youth aged 12–18 years found there was high unprompted recall (41%) and understanding (79%) of the Sun Sound message. The Sun Sound was found to be an effective cue to action in prompting sun protection behaviors when heard, with over a third (38%) of respondents reporting use of additional sun protection upon hearing the jingle. Since the pilot, the Sun Sound has expanded to over 60 pools, beaches, and selected venues across Australia. The campaign demonstrates it is possible to influence behavior by targeting audiences at the actual point that behavior occurs, using research-informed insights and a relevant marketing mix.
32
Damianovich, D., M. Adena, and N. Tebbutt. "Patterns of use and outcomes with irinotecan and oxaliplatin in the treatment of 5-fluorouracil (5-FU) refractory metastatic colorectal cancer: An Australian population based analysis." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 3630. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3630.
Повний текст джерелаАнотація:
3630 Background: Randomised clinical trials have established an important role for oxaliplatin (O) and irinotecan (I) in the management of advanced colorectal cancer (CRC). However, patients (pts) enrolled in clinical studies represent a restricted population and little is known about the use of O and I in the general population and the subsequent outcomes outside clinical studies. We used the Australian Health Insurance Commission (HIC) database to describe prescribing patterns of O and I and their impact on survival in all patients with 5-FU refractory CRC in Australia in 2002 and 2003. Methods: The Australian HIC database was searched to identify all patients with 5-FU refractory CRC who received initial treatment with either O or I in 2002 and 2003. Survival of patients was determined based on subsequent receipt of any other prescriptions for other medication identified in the HIC database. Results: 2999 patients received initial treatment with O or I in Australia in 2002 and 2003. 62% of pts were male and 23% and 2% were aged ≥70 years and ≥80 years respectively. There was a marked increase in initial treatment with O rather than I; 48% of pts received O first in 2002 versus 66% in 2003 (p<0.001). Overall 40–45% of pts received both O and I, however younger pts were more likely to receive both drugs (p<0.001). After 5-FU failure and treatment with O or I, estimated 6-month and 12-month survival was 0.67 (95% CI 0.66–0.69) and 0.42 (95% CI 0.40–0.44) respectively. Six and twelve month survival was superior for pts who received both O and I, however the sequence of O and I had no impact on survival. Survival of older pts (≥70 years) was inferior to younger pts no matter whether O or I was used as initial treatment. Conclusions: Analysis of the Australian HIC database provides a valuable means of assessing patterns of use and outcomes of new therapies. This type of analysis could also be used to evaluate other new agents. [Table: see text]
33
Yu, X. Q., D. L. O'Connell, and D. Forman. "Comparison of cancer survival in UK and Australia: rates are higher in Australia for three major sites." British Journal of Cancer 91, no. 9 (October 12, 2004): 1663–65. http://dx.doi.org/10.1038/sj.bjc.6602154.
Повний текст джерела
34
Heard, Adrian, David Roder, and Colin Luke. "Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia)." Cancer Causes & Control 16, no. 5 (June 2005): 475–81. http://dx.doi.org/10.1007/s10552-004-8023-0.
Повний текст джерела
35
Olver, Ian, Franca Marine, and Paul Grogan. "Disparities in Cancer Care in Australia and the Pacific." Oncologist 16, no. 7 (March 16, 2011): 930–34. http://dx.doi.org/10.1634/theoncologist.2010-0404.
Повний текст джерела
36
Burkitt, V. "Report Outlines Plan to Reform Cancer Care in Australia." JNCI Journal of the National Cancer Institute 95, no. 9 (May 7, 2003): 641–43. http://dx.doi.org/10.1093/jnci/95.9.641.
Повний текст джерела
37
Girschik, J., Lin Fritschi, T. Threlfall, and T. Slevin. "Deaths from non-melanoma skin cancer in Western Australia." Cancer Causes & Control 19, no. 8 (April 2, 2008): 879–85. http://dx.doi.org/10.1007/s10552-008-9150-9.
Повний текст джерела
38
Baade, Peter, P. Carrière, and L. Fritschi. "Trends in testicular germ cell cancer incidence in Australia." Cancer Causes & Control 19, no. 10 (May 14, 2008): 1043–49. http://dx.doi.org/10.1007/s10552-008-9168-z.
Повний текст джерела
39
Walia, Anuj, Xuan Wang, Martha Nicholson, Lucy Sun, Jessica R. Wong, Jennifer Eriksson, Smita Kothari, and Edith Morais. "Epidemiological trends of HPV-related anal cancers amongst males globally: A systematic literature review." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 492. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.492.
Повний текст джерелаАнотація:
492 Background: Anal cancer is associated with human papillomavirus (HPV), a sexually transmitted infection, which can be prevented by the HPV vaccination. Few countries do recommend vaccination for the male population, but all males are at risk of contracting HPV. This study aimed to identify the latest evidence on the incidence of anal cancer and pre-cancer related to HPV in males globally and to analyze the epidemiological trends. Methods: A systematic literature search was performed using Medline and EMBASE. Studies containing original anal cancer incidence data in males published between January 1, 2008 and March 23, 2018 in English were included. Results: The global incidence of anal cancers and pre-cancers among the general male population was identified in 25 studies with observations ranging between 1968 and 2014. Incidence over time was reported in Australia and Europe. In an Australian national study, anal cancer incidence increased from 0.77 to 1.3 per 100,000 persons from 1982-2005, and in the UK from 0.79 to 1.06 per 100,000 persons from 1962-2002. In Denmark, the anal cancer range increased from 0.20-0.41 to 0.69-1.3 per 100,000 person-years (PYs) from pre-2000 to post-2000, and in France from 0.2 to 0.5 per 100,000 PYs from 1982-2012. In two national US studies, the mean incidence of pre-cancers was 1.5 in the period 1997-2009, and 0.41 from 1978-2007 per 100,000 PYs. The burden of anal cancers and pre-cancers increased the most among high-risk males reported in US studies. For HIV-positive males, mean incidence of cancer increased from 10.5 during 1980-1989 to 42.3 in 1996-2004 per 100,000 PYs, and for HIV-positive MSM, incidence increased from 47 to 270 per 100,000 PYs between 1984 and 2013. The mean pre-cancer incidence among HIV-positive males increased from 1.7 during 1980-1989 to 29.5 in 1996-2004 per 100,000 PYs. Conclusions: This systematic literature review demonstrates the increase in anal cancer and pre-cancer incidences over time in men, especially in high-risk male populations. The burden of anal cancers and pre-cancers increase over time in all male populations highlights the unmet medical need and the importance of preventative interventions such as HPV gender-neutral vaccinations.
40
Medlow, S., and P. Patterson. "Determining research priorities for adolescent and young adult cancer in Australia." European Journal of Cancer Care 24, no. 4 (February 12, 2015): 590–99. http://dx.doi.org/10.1111/ecc.12291.
Повний текст джерела
41
Dear, Rachel F., Alexandra L. Barratt, Alison Evans, John Simes, John Newsom, Dan Kent, Sally Crossing, et al. "Identifying and prioritising gaps in colorectal cancer trials research in Australia." Medical Journal of Australia 197, no. 9 (November 2012): 507–11. http://dx.doi.org/10.5694/mja12.10623.
Повний текст джерела
42
Pearson, Sallie-Anne, Clare L. Ringland, and Robyn L. Ward. "Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia—Monitoring the Effect of an Expensive Medicine Access Program." Journal of Clinical Oncology 25, no. 24 (August 20, 2007): 3688–93. http://dx.doi.org/10.1200/jco.2007.11.2516.
Повний текст джерелаАнотація:
Purpose Data from clinical trials are used for drug registration; however, many cancer medicines are ultimately used off-label. This study examines the extent to which the clinical practice use of trastuzumab for the treatment of metastatic breast cancer differs from its use under trial conditions. Methods This study involved all women (N = 1,469) with metastatic breast cancer who received trastuzumab in Australia between December 2001 and March 2005. Given that Australia operates a universal health care system, administrative databases could be examined to determine the duration of therapy, rate of off-label use, compliance with cardiac monitoring, and the extent of drug wastage (volume and cost). Results A total of 433 enrollees (29.5%) received trastuzumab as monotherapy and 1,036 enrollees (70.5%) received the drug in combination with chemotherapy. A total of 321 women (22%) received off-label trastuzumab. The median duration of trastuzumab therapy was longer than that on trial: 5.6 v 3.1 months for enrollees receiving monotherapy and 12.5 v 6.9 months for concomitant chemotherapy. Only 47 (3%) of enrollees received cardiac monitoring before and during trastuzumab therapy. We estimated 24% of trastuzumab dispensed was discarded, at a cost of $21.1 million Australian. Alternative administration schedules and the addition of another vial size potentially reduce wastage to 6% of volume dispensed. Conclusion Debates about the use of expensive cancer medicines should consider postmarketing assessments as well as trial experience. The longer duration of trastuzumab use in clinical practice and the high rates of off-label use provide incentive for new clinical trials. Strategies to improve cardiac monitoring and to minimize drug wastage are issues that require immediate attention.
43
Gibson, Edward, Roger Woods, Alexa Potter, Jessica Leigh Reid, Jennie Louise, Gelareh Farshid, Taryn Bessen, and Susan Neuhaus. "Epidemiological trends of dermal sarcoma in Australia." Australasian Journal of Plastic Surgery 2, no. 2 (September 28, 2019): 10–16. http://dx.doi.org/10.34239/ajops.v2n2.127.
Повний текст джерелаАнотація:
Background: Sarcomas comprise a heterogenous group of malignant tumours of mesenchymal origin and can arise in the skin. Definitive management of skin sarcoma usually entails surgical resection with wide margins, often requiring reconstruction. The incidence and demographics of these neoplasms in Australia are poorly understood. Method: Incidence, gender and age distribution data for skin sarcomas for the period 1982–2009 were obtained from the Australian Cancer Database (ACD). Morphology and topographical region coding via the International Classification of Diseases for Oncology third edition (ICD-O-3)1 were used to identify the data.Results: A total of 5453 cases of skin sarcoma in the Australian population were identified over the 28-year period. Anatomically, 1610 cases (29%) occurred on the limbs, 1416 (26%) on the head and neck area, 957 (18%) on the trunk and 1470 (27%) had an unspecified skin origin. Overall incidence was 2.09 per 100,000 population. Males were more commonly affected (70%), most commonly in the 30–49 years and 70+ years age groups. The most common pathological subtypes were fibromatous sarcoma (including dermatofibrosarcoma protuberans), Kaposi’s sarcoma and pleomorphic dermal sarcoma.Conclusion: The Australian Cancer Database data used to describe the pattern and epidemiological trends for skin sarcoma in Australia demonstrated variation from international trends and highlight the need for further research into the aetiology of these tumours.
44
Dessaix, A. "Implementation Learnings From a Cancer-Prevention Multirisk Factor Public Education Campaign." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 133s. http://dx.doi.org/10.1200/jgo.18.50200.
Повний текст джерелаАнотація:
Background and context: The Cancer Council New South Wales (CCNSW) is one of Australia's leading cancer charities and is uniquely 95% community funded. Cancer prevention is one of five strategic priority areas for CCNSW. An estimated to 37,000 cancer cases are preventable each year in Australia; 33% of cancers in men and 31% in women. The CCNSW developed and implemented the 1 in 3 Cancers Campaign in 2016, the first Australian multirisk factor cancer prevention campaign. This was also the organization's first experience in implementing a social marketing mass media campaign. Over two years, the campaign's primary objective was to raise awareness that one in three cancers are preventable, to highlight why preventing cancer is important and practical steps for prevention. Aim: To undertake an organizational review of internal learnings from the development, implementation and evaluation of the 1 in 3 Cancers Campaign and make recommendations for future campaign practice. Strategy/Tactics: Cross-organizational perspectives were provided from 20 Cancer Council staff from the areas of cancer prevention, research, fundraising and community engagement through a one-day workshop. Program/Policy process: Workshop participants: 1) reviewed best practice social marketing processes, 2) reviewed published evidence on mass media public education campaigns, 3) against this framework, determined internal organizational learnings from the 1 in 3 Cancers Campaign and made recommendations for future practice. Outcomes: A summary report of key lessons learnt from the implementation of the 1 in 3 Cancers Campaign and recommendations for future practice. What was learned: Areas of strengths were identified including cross-organizational collaboration, the development of an interactive cancer risk quiz, good community awareness of the campaign and key message take out. Areas for improvement included the need for greater resource investment (namely staff capacity, skills and budget), greater lead times for thorough campaign planning and the need to focus on singular behavioral cancer risk factors in communication messaging rather than multiple risk factors. The workshop concluded that well-planned, well-resourced mass media campaigns were an important evidence-based strategy for future cancer prevention practice.
45
Ong, Wee Loon, Farshad Foroudi, and Jeremy Laurence Millar. "Australian population-based study of single- versus multi-fraction palliative radiotherapy for bone metastases." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 6568. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.6568.
Повний текст джерелаАнотація:
6568 Background: Single fraction palliative radiotherapy (SFRT) has been shown to be equivalent to multi-fraction radiotherapy (MFRT) for bone metastases symptom management. Remuneration for radiotherapy (RT) in Australia are largely determined by fractions delivered. We aim to determine the use of SFRT for bone metastases in Australia. Methods: We did a population-based linkage study of multiple administrative healthcare databases in Victoria, Australia: the Victorian Radiotherapy Minimum Data Set (VRMDS), the Victorian Cancer Registry (VCR), and the Birth, Death and Marriage registry (BDM). All patients with solid tumour (excluding primary bone cancer) who received palliative radiotherapy for bone metastases between 2012 and 2017 were included. The primary outcome was use of SFRT. The Cochrane-Armitage test for trend was used to evaluate SFRT use over time. Multivariable logistic regression was used to identify factors associated with SFRT use. Results: A total of 15,668 courses of RT for bone metastases were delivered to 10,351 patients. The overall proportion of SFRT was 18% (2,746/ 15,668). There was no significant change in SFRT use over time, from 18% in 2012 to 20% in 2017 (P = 0.06). Older patients were more likely to have SFRT (mean age 69.4 vs. 68.2, P < 0.001). Patients who had lung cancer (21%) and prostate cancer (19%) were more likely to have SFRT compared to other tumour types (P < 0.001). Spine RT was associated with lower use of SFRT compared to other treatment sites (14% vs. 22%, P < 0.001). Patients from remote area were more likely to have SFRT compared to patients from major cities (22% vs. 17%, P < 0.001). Patients treated in private institutions were less likely to have SFRT compared to those treated in public institutions (10% vs. 22%, P < 0.001). In multivariate analyses, patients’ age, tumour type, area of residence, and treatment institutions were independently associated with SFRT use. Conclusions: This is the largest Australian population-based cohort treated with RT for bone metastases, with low utilisation of SFRT over time. There is large variation in SFRT use depending on patient-, tumour-, geographical and institutional factors. Further work is needed to increase uptake, and reduce unwarranted variation, in SFRT use.
46
Davis, Ian D., Sze Ting Lee, Lekshmy Shanker, David Clouston, Damien M. Bolton, David Angus, David Webb, et al. "11C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 182. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.182.
Повний текст джерелаАнотація:
182 Background: A decision to treat prostate cancer (PC) with radical prostatectomy (RP) with curative intent requires confidence that the PC is confined to the prostate. PC outcomes will improve with better selection of surgical candidates. Current imaging modalities include CT and MRI but have limited accuracy. We assessed 18F-FDG (FDG) and 11C-choline (CHOL) PET in men planned for RP to determine the accuracy of PET, effects of PET on decision making by surgeons, and correlation with PSA. Methods: Written informed consent was obtained from eligible participants (pts) planned for RP. All men underwent TRUS-guided prostatic biopsies, CT and MRI scans, PSA and standard tests of organ function. The urologist then documented the treatment plan based on these results. Pts then underwent FDG and CHOL PET and the urologist then determined whether this information altered the treatment plan. After surgery the RP specimen was reconstructed, examined histologically and correlated with TRUS and imaging results on a sextant-based analysis (apex/mid/base on both sides). Results: 30 pts entered and completed the trial. Outcomes are shown in the table. Neither PET modality significantly affected decisions about surgery. Preoperative PSA did not correlate with degree of involvement. FDG PET was unhelpful. Conclusions: CHOL PET was the most sensitive and most accurate modality with highest congruity with pathology and had excellent positive predictive value, but was least specific. CHOL PET was superior to both TRUS biopsy and MRI. Supported by grant 487916 through Cancer Australia, Prostate Cancer Foundation Australia, Australian Government Department of Health and Aging. [Table: see text]
47
Chaturvedi, Anil K., William F. Anderson, Joannie Lortet-Tieulent, Maria Paula Curado, Jacques Ferlay, Silvia Franceschi, Philip S. Rosenberg, Freddie Bray, and Maura L. Gillison. "Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers." Journal of Clinical Oncology 31, no. 36 (December 20, 2013): 4550–59. http://dx.doi.org/10.1200/jco.2013.50.3870.
Повний текст джерелаАнотація:
Purpose Human papillomavirus (HPV) has been identified as the cause of the increasing oropharyngeal cancer (OPC) incidence in some countries. To investigate whether this represents a global phenomenon, we evaluated incidence trends for OPCs and oral cavity cancers (OCCs) in 23 countries across four continents. Methods We used data from the Cancer Incidence in Five Continents database Volumes VI to IX (years 1983 to 2002). Using age-period-cohort modeling, incidence trends for OPCs were compared with those of OCCs and lung cancers to delineate the potential role of HPV vis-à-vis smoking on incidence trends. Analyses were country specific and sex specific. Results OPC incidence significantly increased during 1983 to 2002 predominantly in economically developed countries. Among men, OPC incidence significantly increased in the United States, Australia, Canada, Japan, and Slovakia, despite nonsignificant or significantly decreasing incidence of OCCs. In contrast, among women, in all countries with increasing OPC incidence (Denmark, Estonia, France, the Netherlands, Poland, Slovakia, Switzerland, and United Kingdom), there was a concomitant increase in incidence of OCCs. Although increasing OPC incidence among men was accompanied by decreasing lung cancer incidence, increasing incidence among women was generally accompanied by increasing lung cancer incidence. The magnitude of increase in OPC incidence among men was significantly higher at younger ages (< 60 years) than older ages in the United States, Australia, Canada, Slovakia, Denmark, and United Kingdom. Conclusion OPC incidence significantly increased during 1983 to 2002 predominantly in developed countries and at younger ages. These results underscore a potential role for HPV infection on increasing OPC incidence, particularly among men.
48
Feng, Y., and A. Elshaug. "The Association of Neighbourhood Built and Social Environment and Cancer: Evidence From Australia." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 135s. http://dx.doi.org/10.1200/jgo.18.75400.
Повний текст джерелаАнотація:
Background and context: Australia is among the worst countries in terms of cancer incidence and displays substantial variations in cancer outcomes across multiple geographic scales. Aim: This research project aims to examine how neighborhood social and environmental attributes interact with individual risk factors, affect cancer outcomes and contribute to the geographic variations in cancer outcomes. Specifically, it will answer the following research questions: What neighborhood built and social environment attributes are associated with individual health outcomes? How do neighborhood features influence cancer outcomes, at multiple geographic scales? At what geographical scales the variations in cancer outcomes are the most pronounced and how much is contributed by neighborhood attributes? What initiatives and guidelines should be developed and at what level: local neighborhood, regional, state, national level? Strategy/Tactics: Innovative geospatial techniques will be developed to analyze cancer risk factors and variations at multiple spatial levels utilizing population-based hospital inpatient data in NSW, Australia Program/Policy process: The study is the first population-based study evaluating how neighborhood influences cancer outcomes from multiple scales in the Australian context. The project has tangible potentials to be translated into initiatives and practices. This includes various levels such as local neighborhood, state and national level for the prevention and control of cancer and ultimately improve cancer outcomes in Australia. Outcomes: A large proportion of geographic variations in cancer outcomes are contributed by differences in the neighborhood built and social environment characteristics, which interact with individual risk factors and have synergistic effects on cancer outcomes. What was learned: Neighborhood physical and social environment has a strong effect on cancer outcomes. Through modification of neighborhood attributes, we can reduce the exposure to neighborhood risk factors and promote healthy lifestyle choices, which, in turn, reduce cancer incidence and improve survival rates. Effective initiatives and guidelines for cancer control should be developed and at all government levels including the local neighborhood, regional, state, national level.
49
Slevin, T. J., and S. L. McCoy. "???Me No Fry??? in Western Australia." Melanoma Research 7, Supplement 1 (June 1997): S17. http://dx.doi.org/10.1097/00008390-199706001-00057.
Повний текст джерела
50
Barreto, Savio George. "Pancreatic cancer in Australia: is not it time we address the inequitable resource problem?" Future Oncology 16, no. 19 (July 2020): 1385–92. http://dx.doi.org/10.2217/fon-2020-0109.
Повний текст джерелаАнотація:
The present study reviewed the geographical variations in the delivery of pancreatic cancer therapy and whether this impacts overall survival. The evidence suggests a difference in the accessibility of pancreatic cancer care to patients in rural as compared with urban Australia. While centralization of pancreatic surgery is essential to deliver high quality care to patients, it may be interfering with the ease of access of this form of care to patients in regional areas. Access to chemotherapy in regional Australia is also limited. There is need for a concerted effort to improve the overall care and uptake of medical services to patients in metropolitan and remote Australia with the overarching aim of improving survival and meaningful quality of life.